Driehaus Capital Management LLC Purchases 203,300 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Driehaus Capital Management LLC boosted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 126.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 364,463 shares of the company’s stock after acquiring an additional 203,300 shares during the period. Driehaus Capital Management LLC owned 0.96% of Tarsus Pharmaceuticals worth $9,906,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Scientech Research LLC acquired a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at about $289,000. The Manufacturers Life Insurance Company lifted its holdings in Tarsus Pharmaceuticals by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 33,282 shares of the company’s stock valued at $905,000 after buying an additional 3,112 shares during the period. Millennium Management LLC boosted its stake in Tarsus Pharmaceuticals by 1,259.3% in the second quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after acquiring an additional 322,942 shares during the last quarter. Dark Forest Capital Management LP acquired a new stake in Tarsus Pharmaceuticals during the 2nd quarter worth $202,000. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $273,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on TARS shares. Oppenheimer reaffirmed an “outperform” rating and set a $63.00 price objective (up from $61.00) on shares of Tarsus Pharmaceuticals in a research note on Friday, August 9th. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $51.60.

Tarsus Pharmaceuticals Stock Down 1.9 %

NASDAQ:TARS opened at $32.51 on Monday. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -6.82 and a beta of 1.06. The company has a current ratio of 7.03, a quick ratio of 6.99 and a debt-to-equity ratio of 0.28. The stock has a 50-day moving average price of $27.96 and a two-hundred day moving average price of $31.00. Tarsus Pharmaceuticals, Inc. has a 1 year low of $12.57 and a 1 year high of $42.50.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. The firm had revenue of $40.81 million for the quarter, compared to analyst estimates of $31.30 million. During the same quarter in the previous year, the firm posted ($1.17) earnings per share. As a group, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.68 earnings per share for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.